Friday, March 20

Healthcare

Catalent ends FY24 on a strong note ahead of Novo buyout

08/30/20241 Min Read

ahead buyout Catalent ends FY24 note Novo Strong

Previous ArticleBrookfield in talks with sovereign funds over Grifols bid: report

Next Article J&J submits FDA application for myasthenia gravis drug nipocalimab